# VK2735 for Weight Management Type 2 Diabetes Phase 3 (VANQUISH 2)

> **NCT07104383** · PHASE3 · ACTIVE_NOT_RECRUITING · sponsor: **Viking Therapeutics, Inc.** · enrollment: 1100 (estimated)

## Conditions studied

- Weight Loss

## Interventions

- **DRUG:** VK2735

## Key facts

- **NCT ID:** NCT07104383
- **Lead sponsor:** Viking Therapeutics, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2025-06-23
- **Primary completion:** 2027-07-01
- **Final completion:** 2027-08-01
- **Target enrollment:** 1100 (ESTIMATED)
- **Last updated:** 2026-04-07


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07104383

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07104383, "VK2735 for Weight Management Type 2 Diabetes Phase 3 (VANQUISH 2)". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT07104383. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*